Review anchor
Nuclear receptor subfamily 4immunitygroup A member 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Nuclear receptor subfamily 4immunitygroup A member 1
CHEMBL1293229
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Nuclear receptor subfamily 4immunitygroup A member 1 as ChEMBL target CHEMBL1293229, mapped to UniProt P22736. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1293229
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22736
Nuclear receptor subfamily 4immunitygroup A member 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Nuclear receptor subfamily 4immunitygroup A member 1 matters
Nuclear receptor subfamily 4immunitygroup A member 1 is reviewed as Nuclear receptor subfamily 4immunitygroup A member 1 (UniProt P22736); the current evidence base includes 3 approved drugs, 460 compounds, and 189 assays, with lead potency reaching pChEMBL 9.9.
Protein context
Nuclear receptor subfamily 4immunitygroup A member 1
Nuclear receptor subfamily 4immunitygroup A member 1 Sequence length is 598 aa.
Review this target as Nuclear receptor subfamily 4immunitygroup A member 1, mapped to UniProt P22736. Sequence length is 598 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P22736
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 460 compounds, and 189 assays for this target. The dominant activity type is IC50. CHEMBL1221517 is the current potency anchor at pChEMBL 9.9.
Use CHEMBL1221517 as the tractability anchor when discussing potency (pChEMBL 9.9).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 9.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Nuclear receptor subfamily 4immunitygroup A member 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22736, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
460
Total Compounds
189
Total Assays
3
Approved Drugs
IC50: 238.0, EC50: 73.0, KD: 50.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1221517
|
9.9 | EC50 | — |
|
|
No preferred name
CHEMBL4867199
|
7.5 | Kd | — |
|
|
No preferred name
CHEMBL4857769
|
7.4 | Kd | — |
|
|
No preferred name
CHEMBL5427562
|
7.4 | EC50 | — |
|
|
No preferred name
CHEMBL5413288
|
7.0 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ALITRETINOIN
CHEMBL705
|
1999 |
Source Header